Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of elevated troponin I after percutaneous coronary intervention.
Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM, Topol EJ, Ohman EM; SYMPHONY and 2nd SYMPHONY Cardiac Markers Substudy Investigators. Cantor WJ, et al. Among authors: topol ej. J Am Coll Cardiol. 2002 Jun 5;39(11):1738-44. doi: 10.1016/s0735-1097(02)01877-6. J Am Coll Cardiol. 2002. PMID: 12039485 Free article. Clinical Trial.
Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.
Mukherjee D, Gurm H, Tang WH, Roffi M, Wolski K, Moliterno DJ, Guetta V, Ardissinio D, Bode C, Steg G, Lincoff AM, Topol EJ. Mukherjee D, et al. Among authors: topol ej. Am J Cardiol. 2002 Dec 1;90(11):1198-203. doi: 10.1016/s0002-9149(02)02834-5. Am J Cardiol. 2002. PMID: 12450598 Clinical Trial.
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
Cho L, Chew DP, Moliterno DJ, Roffi M, Ellis SG, Franco I, Bajzer C, Bhatt DL, Dorosti K, Simpfendorder C, Tuzcu M, Yadav JS, Brener S, Raymond R, Whitlow P, Topol EJ, Lincoff AM. Cho L, et al. Among authors: topol ej. Am J Cardiol. 2003 Mar 15;91(6):742-3. doi: 10.1016/s0002-9149(02)03420-3. Am J Cardiol. 2003. PMID: 12633814 Clinical Trial. No abstract available.
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.
Ross MJ, Herrmann HC, Moliterno DJ, Blankenship JC, Demopoulos L, DiBattiste PM, Ellis SG, Ghazzal Z, Martin JL, White J, Topol EJ. Ross MJ, et al. Among authors: topol ej. J Am Coll Cardiol. 2003 Sep 17;42(6):981-8. doi: 10.1016/s0735-1097(03)00913-6. J Am Coll Cardiol. 2003. PMID: 13678916 Free article. Clinical Trial.
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ; TARGET Investigators. Chan AW, et al. Among authors: topol ej. J Am Coll Cardiol. 2003 Oct 1;42(7):1188-95. doi: 10.1016/s0735-1097(03)00944-6. J Am Coll Cardiol. 2003. PMID: 14522478 Free article. Clinical Trial.
1,218 results